Global /Australia /Healthcare /Biotechnology /LTP

LTR Pharma Ltd.

LTP

• ASX: LTP • Delayed

0.4050AUD -5.8%

0.2864 USD

As of 19 June 2026, LTR Pharma Ltd. has a market cap of $51.64M USD, ranking #30381 globally and #735 in Australia. It ranks #2750 in the Healthcare sector, and #534 in the Biotechnology industry.

Global Rank

30381

Country Rank

735

Sector Rank

2750

Industry Rank

534

Key Stats

Market Cap

$51.64MUSD

73.62M AUD

Enterprise Value

$33.83MUSD

47.84M AUD

Revenue (TTM)

$793.62KUSD

1.13M AUD

EBITDA (TTM)

-$6.92MUSD

-9.78M AUD

Net Income (TTM)

-$6.28MUSD

-8.95M AUD

PS Ratio

65.1

PB Ratio

2.7

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Biotechnology

Founded

2020

Website

ltrpharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-5.8%	-2.4%	1.3%	-31%	-24%	-44%	8%	69%	69%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	LTP LTR Pharma Ltd ISIN: AU0000305294 Shares Out.: Shares Outstanding: 181.778M¹ Shares Float: 106.619M² TV: TradingView: ASX: LTP SA: Stock Analysis: ASX: LTP YF: Yahoo Finance: LTP.AX GF: Google Finance: ASX: LTP BA: Barron's: LTP MS: Morningstar: XASX: LTP	0.4050 AUD	TV: TradingView: ASX: LTP SA: Stock Analysis: ASX: LTP YF: Yahoo Finance: LTP.AX GF: Google Finance: ASX: LTP BA: Barron's: LTP MS: Morningstar: XASX: LTP

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About LTR Pharma Ltd.

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.

Similar Companies

Industry: Biotechnology (Australia)

Name	Market Cap (USD) diff.	PE	Country
CSL Ltd. ASX: CSL	$42.27B 60.27B AUD 82K%	29.3	Australia
Telix Pharmaceuticals Ltd. ASX: TLX	$3.57B 5.09B AUD 7K%	-	Australia
Mesoblast Ltd. ASX: MSB	$2.02B 2.88B AUD 4K%	-	Australia
PolyNovo Ltd. ASX: PNV	$489.42M 697.75M AUD 848%	71.8	Australia
Kazia Therapeutics Ltd. NASDAQ: KZIA	$141.64M 174%	-	Australia
Immutep Ltd. ASX: IMM	$65.12M 92.84M AUD 26%	-	Australia

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 353K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 310K%	19.0	United States
argenx SE EBR: ARGX	$47.76B 41.39B EUR 92K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.23B 68.19T KRW 86K%	35.5	South Korea
Lonza Group AG SIX: LONN	$42.29B 33.71B CHF 82K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$27.74B 42.76T KRW 54K%	43.8	South Korea

chevron_leftBack